PLEASANTON, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in products to treat cardiovascular disease, said today that it will be participating in the Raymond James 28th Annual Institutional Investor Conference on Tuesday, March 6.
David Smith, executive vice president and chief financial officer, will provide an update on the company, beginning at 2:50 p.m., Eastern Standard Time (11:50 a.m., Pacific Standard Time).
The presentation will be available through the conference website at http://www.wsw.com/webcast/rj26/thor/, and on the company’s website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company’s product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 11,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web site at http://www.thoratec.com or http://www.itcmed.com.
TNR-435
Thoratec Corporation
CONTACT: David Smith, Executive Vice President, Chief Financial Officer ofThoratec, +1-925-847-8600; or Neal Rosen of Kalt Rosen & Co.,+1-415-397-2686, for Thoratec
Web site: http://www.thoratec.com//
